Agreement leverages Xanadu’s novel poly(amine-co-ester), or PACE, a next generation polymer nanoparticle delivery platform that allows for specific and efficient delivery of nucleic acids, including mRNA and saRNA
NEW HAVEN, Conn., January 10, 2025 — Xanadu Bio, a privately held biotechnology company focusing on next generation delivery of messenger RNA (mRNA), self-amplifying RNA (saRNA), and other nucleic acids, today announced an agreement with Johnson & Johnson.* The agreement uses Xanadu’s PACE polymer nanoparticle platform in development of potentially novel drugs.
“We look forward to the opportunity to apply our PACE platform to develop novel targeted RNA therapeutics,” stated Bruce Turner, M.D., Ph.D. President and Chief Executive Officer of Xanadu Bio. “We look forward to exploring the opportunity to evaluate our propriety platform for additional indications of interest.”
*Legal entity Johnson & Johnson Enterprise Innovation Inc.
About Xanadu Bio
Xanadu Bio is a privately held, next generation nanoparticle delivery company focusing on the delivery of mRNA and other nucleic acids that utilizes PACE platform technology. PACE technology is a next-generation polymeric nanoparticle that consists of three monomers that are fully biodegradable and allows for efficient delivery of and protection from nuclease degradation for different types of nucleic acids, including mRNA. PACE is easily manufactured, cost effective, scalable and can be functionalized to allow both organ and cell specific delivery of its nucleic acid payload. PACE is formulated and optimized to allow safe delivery either systemically or intranasally. Xanadu is leveraging PACE across multiple therapeutic indications, including oncology, immunology, and vaccines. https://xanadubio.com
Contacts
Business Development
Taylor Feehley
Chief Operation Officer, Xanadu Bio
taylorfeehley@xanadubio.com
Investor & Media
Marcy Nanus
Managing Partner, Trilon Advisors, LLC
mnanus@trilonadvisors.com